Fondaparinux in XXXX .

@entity1 @entity1187 @entity548 @entity63 @entity27408 @entity715 @entity1211 @entity6236
Antithrombotic therapies form the cornerstone of management of @entity1187 ( @entity1187 ). An ideal antithrombotic agent should reduce @entity63 complications while keeping @entity548 events to a minimum. Heparins, both unfractionated and low molecular weight, reduce @entity63 outcomes but also significantly increase the risk of major and @entity548 . Moreover, they do not reduce mortality. Therefore, there is a need for newer agents that preserve the benefits of @entity63 reduction while decreasing mortality and @entity548 risk. Fondaparinux is a synthetic pentasaccharide which specifically targets @entity6236 of the coagulation cascade. It has been effectively used in the prevention of and treatment of @entity1211 . Two large randomized controlled trials of fondaparinux compared to unfractionated and low molecular weight heparins, among @entity1 with @entity1187 have recently been completed. These studies have shown a significantly lower risk of @entity548 with fondaparinux compared to heparins, with equivalent or greater reductions in @entity63 outcomes. A small but definite increase in the risk of catheter-related @entity715 has been found among @entity1 undergoing coronary interventions, which is ameliorated by the administration of unfractionated heparin. This review outlines the pharmacological properties of @entity27408 and critically examines the available clinical trial data for fondaparinux in @entity1187 .
